menu
Investors & Media

Press Releases

Press Releases

Keyword Search

Dec 12, 2019
Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024
Dec 02, 2019
Ionis Pharmaceuticals to hold technology webcast
Nov 25, 2019
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
Nov 19, 2019
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
Nov 12, 2019
Ionis Pharmaceuticals to present at upcoming investor conferences
Nov 06, 2019
Ionis provides third quarter financial results and improved 2019 guidance
Oct 28, 2019
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
Oct 23, 2019
Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences
Oct 22, 2019
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
Oct 10, 2019
Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
Oct 09, 2019
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Oct 07, 2019
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
Sep 25, 2019
Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year
Sep 16, 2019
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
Aug 29, 2019
Akcea and Ionis to present new data for TEGSEDI and AKCEA-TTR-LRx at two upcoming medical meetings
Aug 28, 2019
Ionis Pharmaceuticals to present at upcoming investor conferences
Aug 27, 2019
Ionis licenses hepatitis B program to GSK
Aug 07, 2019
New England Journal of Medicine publishes results from pivotal study of WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome
Aug 07, 2019
Ionis Reports Second Quarter 2019 Financial Results
Aug 06, 2019
Akcea and Ionis report top-line results from the BROADEN Study with WAYLIVRA® (volanesorsen) in patients with familial partial lipodystrophy
Jul 30, 2019
Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
Jun 26, 2019
Akcea and Ionis announce upcoming data presentations at the 5th European Academy of Neurology Annual Congress
Jun 20, 2019
Akcea and Ionis announce upcoming data presentations at the 2019 Peripheral Nerve Society Annual Meeting
Jun 18, 2019
Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
Jun 12, 2019
Ionis announces appointment of Joan E. Herman to its board of directors
Jun 06, 2019
Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders
May 09, 2019
Ionis reports first quarter 2019 financial results
May 07, 2019
New long-term TEGSEDI safety and efficacy data featured as an oral presentation at 2019 American Academy of Neurology Annual Meeting (AAN)
May 07, 2019
Akcea and Ionis announce approval of WAYLIVRA® (volanesorsen) in the European Union
May 06, 2019
Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
May 01, 2019
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
Apr 25, 2019
Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast
Apr 08, 2019
Ionis Pharmaceuticals to provide corporate update at 2019 annual meeting of stockholders
Mar 25, 2019
Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
Mar 15, 2019
Akcea and Ionis announce upcoming data presentations at the 2019 American College of Cardiology Meeting (ACC.19)
Mar 07, 2019
Ionis Pharmaceuticals to present at upcoming investor conferences
Mar 01, 2019
Akcea and Ionis receive positive EU CHMP opinion for WAYLIVRA (volanesorsen)
Feb 27, 2019
Ionis exceeds 2018 financial guidance
Feb 25, 2019
AKCEA-APO(a)-LRx advances as leading pharmaceutical company exercises option to license
Feb 13, 2019
Ionis Pharmaceuticals to hold 2018 financial results webcast
Jan 28, 2019
First patient enrolled in pivotal study of RG6042 (IONIS-HTT Rx) for people with Huntington's Disease
Jan 02, 2019
Ionis Pharmaceuticals to present at 37th Annual J.P. Morgan Healthcare Conference
Load More »